BioLargo Subsidiary Clyra Medical Technologies Adds Two Medical Industry Veterans to its Board of Directors

BioLargo Subsidiary Clyra Medical Technologies Adds Two Medical Industry Veterans to its Board of Directors

WESTMINSTER, CA / ACCESSWIRE / February 20, 2023 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech systems and entire-provider environmental engineering business, announced that its subsidiary Clyra Health care Systems, Inc. has added two health-related field veterans as new associates of its board of directors: Nicholas Valeriani and Linda Park.

Nicholas Valeriani has many years of government practical experience in the health care product marketplace. He used 34 several years at Johnson & Johnson, wherever he led several corporate capabilities and was a member of its govt committee. Key positions provided corporate vice president of human methods, globally chairman of health-related gadgets & diagnostics, and Vice President in the Place of work of Method and Expansion. He at the moment serves on the board of directors for Edwards Lifesciences, Surgalign, Inc., SPR Therapeutics, and AgNovos Bioscience. Mr. Valeriani also serves on the board of the Gary and Mary West Health Institute, an unbiased non-financial gain healthcare research corporation whose mission is to help seniors to correctly age in position with obtain to significant high quality, very affordable health care and support products and services. Mr. Valeriani holds a bachelor’s diploma in Industrial Engineering and an MBA from Rutgers University.

Linda Park is a trusted executive and lawful professional with a established track document of supporting and advising public companies. With company board and executive working experience at billion-dollar corporations this sort of as her recent roles performing with Edwards Lifesciences in her capability as Corporate Secretary, Senior Vice President and Associate Basic Counsel, and Board Member of the Edwards Lifesciences Basis, and prior operate with Western Digital Corporation, Linda provides about 20 yrs of experience advancing organizations’ company governance and strategic plans. She also has several years of experience advising issuer and investment decision banking customers on corporate and securities matters, mergers and acquisitions, financial institution financings and money marketplaces, which includes preliminary general public choices. She is also an active partner and assumed chief on environmental, social, and company governance challenges. Linda has an undergraduate degree from Johns Hopkins University, and a law degree from Duke University Faculty of Law.

“We are so happy that Nicholas and Linda have joined Clyra’s board of directors,” stated Steve Harrison, President of Clyra Health care Systems. “Nicholas and Linda the two have intensive practical experience in the health-related market effectively executing on assignments to just take health care merchandise to current market – a monumental endeavor we are at present engaged in. We believe that their abilities will be priceless as Clyra performs to execute agreements in licensing, distributing, and promoting its progressive professional medical solutions, which includes its first – BioClynse, a patented, Fda 510(k)-cleared wound irrigation product or service that is gentle but productive while not making antimicrobial resistance.”

Dennis P. Calvert, President and CEO of BioLargo, commented on the information, “We are so delighted that Clyra now has a clear route ahead of them to commercialize the remarkable merchandise they developed dependent off of BioLargo’s patented technologies. We know that with experts like Nicholas Valeriani and Linda Park delivering vital steering, Clyra’s future is extremely vibrant.”

About BioLargo, Inc.
BioLargo, Inc. (OTCQB:BLGO) is a cleantech and lifestyle sciences innovator and engineering companies option company. Our main items tackle PFAS contamination, accomplish sophisticated water and wastewater therapy, command odor and VOCs, boost air high-quality, and regulate infections and infectious sickness. Our tactic is to invent or obtain novel technologies, create them into product or service choices, and lengthen their professional access by means of licensing and channel partnerships to increase their affect. See our website at www.BioLargo.com.

Speak to Details
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Secure Harbor Act
This push release contains ahead-looking statements in just the this means of the Private Securities Litigation Reform Act of 1995. These forward-searching statements contain devoid of limitation those people about BioLargo’s (the “Firm”) expectations with regards to anticipated profits and designs for future operations, and may well be recognized by words these kinds of as “we imagine”. These statements contain dangers and uncertainties, and genuine success may perhaps differ materially from any foreseeable future success expressed or implied by the ahead-hunting statements. Pitfalls and uncertainties consist of with out limitation: the influence of the COVID-19 pandemic on the Firm’s organization, success of functions, economic affliction, and stock rate the result of worldwide and regional economic circumstances on the Firm’s enterprise, including effects on buying decisions by customers and companies the capacity of the Company to contend in marketplaces that are highly competitive and subject matter to rapid technological alter the ability of the Organization to control recurrent introductions and transitions of products and solutions and companies, like offering to the marketplace, and stimulating client demand for, new solutions, solutions, and technological improvements on a well timed basis the dependency of the Business on the functionality of distributors of the Firm’s goods. Much more information and facts on these hazards and other prospective elements that could have an impact on the Company’s company and money outcomes is integrated in the Company’s filings with the SEC, together with in the “Possibility Aspects” and “Management’s Dialogue and Analysis of Financial Problem and Outcomes of Functions” sections of the Company’s most not long ago submitted periodic experiences on Type 10-K and Type 10-Q and subsequent filings. The Corporation assumes no obligation to update any forward-wanting statements or details, which converse as of their respective dates.

Supply: BioLargo, Inc.

Perspective supply model on accesswire.com:
https://www.accesswire.com/739929/BioLargo-Subsidiary-Clyra-Healthcare-Technologies-Provides-Two-Healthcare-Sector-Veterans-to-its-Board-of-Directors

Corium Pharma Solutions Names Two Industry Veterans to its Executive Team

Corium Pharma Solutions Names Two Industry Veterans to its Executive Team
&#13

 

&#13

&#13

Appointments of Kevin Ostrander to Main Enterprise Officer and Dr. Niraj Vasisht to Main Engineering Officer Further Improve Management Staff

&#13
&#13

GRAND RAPIDS, Mich., Feb. 9, 2023 /PRNewswire/ — Corium Pharma Remedies, Inc. (CPSI), a major, total-service agreement enhancement and manufacturing group specializing in novel drug supply technologies for prescription drug and client solutions like transdermal modalities, has named Kevin Ostrander as Main Small business Officer and Dr. Niraj Vasisht as Main Technological innovation Officer.  These appointments, which include CPSI’s current announcement that Mark Sirgo experienced been named Chief Executive Officer, additional improve CPSI’s government staff and place the enterprise for extended-time period development.

&#13
&#13

Appointments of Kevin Ostrander to Main Small business Officer and Dr. Niraj Vasisht to Chief Technologies Officer

&#13
&#13

Kevin Ostrander delivers additional than 30 years of practical experience as the two a research scientist and small business development qualified in the pharmaceutical field, obtaining labored for several little to mid-sized brand and generic companies. Prior to becoming a member of CPSI, Mr. Ostrander served as Vice President of Business enterprise Development for ApiJect Units, a privately held healthcare device business with proprietary delivery engineering in the sterile injectables sector. Before ApiJect, Kevin was Senior Vice President of Organization Enhancement at BioDelivery Sciences Intercontinental (BDSI) in which he was dependable for concluding the acquisition of the firm by Collegium Pharmaceutical.  Mr. Ostrander retains a BS degree in Biology from the State College of New York at Albany, an MS diploma in Pharmaceutical High-quality Assurance and Regulatory Affairs from Temple College College of Pharmacy and an MBA in Intercontinental Organization from St. Joseph’s University.

&#13
&#13

“Owning worked together at BDSI, I am fired up to crew up with Kevin once more and I know he will perform an instrumental role in shaping our long-phrase advancement strategy,” said Mark Sirgo, CEO of CPSI. “Operating intently with myself, associates of the leadership staff and our buyers, we will concentration on leveraging our current abilities and pinpointing opportunity complimentary acquisitions that will make it possible for us to extend our footprint in the specialty contract manufacturing place.”

&#13
&#13

Dr. Niraj Vasisht brings a lot more than 25 many years of knowledge as an government, entrepreneur, and technological know-how critical-belief-chief in drug delivery to the pharmaceutical business.  Prior to joining CPSI, Dr. Vasisht was President and CEO of Avior Bio, Inc., a clinical-phase, production-integrated pharmaceutical enterprise that was employing drug shipping and delivery to reinvent demonstrated therapeutics for scarce illnesses. Just before Avior, he was the Main Know-how Officer at BDSI wherever he invested 13 decades in multiple roles and oversaw the growth, acceptance, intellectual home creation and production of a few Fda approved solutions utilizing a novel drug shipping and delivery platform. Dr. Vasisht gained a bachelor’s in Chemical Engineering from the Indian Institute of Technological innovation, India, and a Doctorate in Chemical Engineering from Rensselaer Polytechnic Institute. He has about 25 patents, various publications and authored a book on Microencapsulation and Managed Launch.

&#13
&#13

Mr. Sirgo commented, “I worked closely with Niraj for numerous years at BDSI and am thrilled to have the option to lover with him yet again. As Chief Technology Officer, Niraj will enjoy a significant part overseeing the formulation enhancement perform powering all of our CPSI platforms. In addition, he will be primary the evaluation of complimentary platforms for potential acquisition that will allow CPSI to maintain a leadership role in the specialty enhancement and manufacturing sector.”

&#13
&#13

Founded in 1995 in Grand Rapids, Michigan, Corium Pharma Methods has maintained longstanding partnerships with multinational Fortune 500 corporations and pharmaceutical businesses alike. CPSI currently manufactures a range of more than the counter and prescription goods, which includes Proctor & Gamble Co’s (NYSE: PG) total Crest Whitestrips franchise, Agile Therapeutics, Inc.’s (NASDAQ: AGRX) Twirla®, and Corium, LLC’s (“Corium”) ADLARITY®, a the moment-weekly, transdermal donepezil patch for Alzheimer’s clients.

&#13
&#13

About Corium Pharma Methods

&#13
&#13

Headquartered in Grand Rapids, Michigan, Corium Pharma Solutions is a main, total-support deal advancement and producing corporation specializing in novel drug and customer product supply systems. With a observe file spanning just about 30 many years, the enterprise presents finish-to-conclude remedies to its partners, from formulation and product or service progress work, by way of business-scale producing and packaging. The firm’s achievement is enabled by its condition-of-the-art facilities, extremely tenured operational management, and proprietary drug delivery systems, CORPLEX™ and MICROCOR®. Corium Pharma Remedies is jointly owned by B-FLEXION and Webster Fairness Partners. Prior to the CPSI transaction with Webster Fairness Partners in Oct 2022, Gurnet Level Capital, an affiliate of B-Flexion, led the unique financial investment in Corium Pharma Options as a result of a consider-private transaction in October 2018.

&#13
&#13

About Gurnet Place Funds & B-FLEXION

&#13
&#13

Gurnet Place Funds, an affiliate of B-FLEXION, is a leading healthcare fund that invests in de-risked lifestyle sciences corporations. Gurnet Stage generally focuses on enterprises that have substantial advancement possible in the late product or service growth and commercialization levels of their evolution. These businesses come to be associates not just simply because of their ability to deliver financial value, but also due to the fact of their prospective to supply social impression. Gurnet Point’s crew of very professional marketplace executives performs intently with its portfolio businesses, with an lively tactic driving operational transformation and outsized returns.
&#13
www.gurnetpointcapital.com/

&#13
&#13

B-FLEXION is a non-public, entrepreneurial investment decision company, partnering with complex money to satisfy the shared goal of offering exceptional worth more than the generations, even though also contributing positively to modern society. The corporation oversees growth-oriented operating firms and asset supervisors, normally with an ‘active owner’ philosophy. B-FLEXION invests across a large range of industries, including healthcare. Gurnet Level Money, an affiliate of B-FLEXION, qualified prospects B-FLEXION’s de-risked existence sciences expense tactic.
&#13
https://www.bflexion.com/

&#13
&#13

About Webster Equity Partners

&#13
&#13

Established in 2003, Webster is a private equity firm that focuses on higher effects progress methods that seek to provide exceptional outcomes for our investors, portfolio organizations and the communities that we provide. Our mission is to provide exceptional returns to our associates by way of the financial commitment in and improvement of purpose driven affected person-centric health care companies committed to supplying very best of class clinical care and company to their patients. https://websterequitypartners.com/

&#13
&#13

Call

&#13
&#13

Gartman PR
&#13
(202) 413-4226

&#13
&#13

Cision Watch unique material:https://www.prnewswire.com/news-releases/corium-pharma-answers-names-two-market-veterans-to-its-govt-group-301742673.html

&#13
&#13

Supply Corium Pharma Alternatives Inc.

&#13

&#13

 

&#13